Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine

BMC Infectious Diseases

Volumn 4, Issue , 2004, Pages

  Santos, Eneida A ^a   Sucupira, Michel V F ^a   Arabe, Juçara ^b   Gomes, Selma A ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b HOSPITAL UNIVERSITÁRIO GAFFRÉE E GUINLE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; DNA POLYMERASE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RIFAMPICIN; SAQUINAVIR; STAVUDINE; VIRUS DNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DNA DIRECTED DNA POLYMERASE; HEPATITIS B SURFACE ANTIGEN;

ADULT; ANTIGENICITY; ARTICLE; BLOOD SAMPLING; CASE REPORT; DISEASE EXACERBATION; DNA DETERMINATION; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; SUPERINFECTION; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN; ANTIVIRAL RESISTANCE; BLOOD; CHEMISTRY; CLASSIFICATION; DRUG EFFECT; FATALITY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; MUTATION; PHYLOGENY; POLYMERASE CHAIN REACTION; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CLONING, MOLECULAR; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FATAL OUTCOME; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MUTATION; PHYLOGENY; POLYMERASE CHAIN REACTION;

EID: 10444284909     PISSN: 14712334     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2334-4-29     Document Type: Article

References (37)

1. Enzensberger R, Braun W, July C, Helm EB, Doerr HW: Prevalence of antibodies to human herpesviruses and hepatitis B virus in patients at different stages of human immunodeficiency virus (HIV) infection. Infection 1991, 19:140-145.
2. Saillour F, Dabis F, Dupon M, Lacoste D, Trimoulet P, Monlun E, Ragnaud JM, Morlat P, Pellegrin JL, Fleury H, Couxigou P: Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine. BMJ 1996, 313:461-464.
3. Twu SJ, Detels R, Nelson K, Visscher BR, Kaslow R, Palenicek J: Relationship of hepatitis B virus infection to human immunodeficiency virus type 1 infection. J Infect Dis 1993, 167:299-304.
4. Santos EA, Yoshida CFT, Rolla VC, Mendes JM, Vieira IF, Arabe J, Gomes SA: Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 2003, 22:92-98.
5. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, Benhamou JP, Erlinger S, Valla D, Marcellin P: Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999, 29 1306-1310.
6. Gilson RJ, Hawkins AE, Beecham MR, Ross E, Waite J, Briggs M: Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997, 11 597-606.
7. Benhamou Y, Dohin E, Lunel-Fabiani F, Poynard T, Huraux JM, Katlama C, Opolon P, Gentilini M: Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995, 345:396-397.
8. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE: Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999, 28 1032-1035.
9. Lai CL, Yuen MF: Profound suppression of hepatitis B virus replication with lamivudine. J Med Virol 2000, 61:367-373.
10. Honkoop P, de Man RA, Zondervan PE, Schalm SW: Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 1997, 17:103-106.
11. Cooley L, Ayres A, Bartholomeusz A, Lewin S, Crowe S, Mijch A, Locarnini S, Sasadeusz J: Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 2003, 17:1649-1657.
12. Thibault V, Benhamou Y, Seguret C, Bochet M, Katlama C, Bricaire F, Opolon P, Poynard T, Agut H: Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol 1999, 37:3013-3016.
13. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001, 33:1527-1532.
14. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW: Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000, 32 635-639.
15. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM: Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999, 30 567-572.
16. Liu CJ, Chen PJ, Lai MY, Kao JH, Chen DS: Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and fulllength viral sequences. Hepatology 2001, 34:583-589.
17. Niel C, Moraes MT, Gaspar AM, Yoshida CF, Gomes SA: Genetic diversity of hepatitis B virus strains isolated in Rio de Janeiro Brazil. J Med Virol 1994, 44:180-186.
18. Gomes SA, Yoshida CF, Niel C: Detection of hepatitis B virus DNA in hepatitis B surface antigen-negative serum by polymerase chain reaction: evaluation of different primer pairs and conditions. Acta Virol 1996, 40:133-138.
19. Van de Peer Y, de Wachter R: TREECON for Windows: a software package for the construction and drawing of evolutionary trees for the Microsoft Windows environment. Comput Applic Biosci 1994, 10:569-570.
20. Bowyer SM, van Staden L, Kew MC, Sim JG: A unique segment of the hepatitis B virus group A genotype identified in isolates from South Africa. J Gen Virol 1997, 78:1719-1729.
21. Kimbi GC, Kramvis A, Kew MC: Distinctive sequence characteristics of subgenotype A1 isolates of hepatitis B virus from South Africa. J Gen Virol 2004, 85:1211-1220.
22. Sugauchi F, Kumada H, Acharya SA, Shrestha SM, Gamutan MT, Khan M, Gish RG, Tanaka Y, Kato T, Orito E, Ueda R, Miyakawa Y, Mizokami M: Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. J Gen Virol 2004, 85 811-820.
23. Araujo NM, Mello FC, Yoshida CF, Niel C, Gomes SA: High proportion of subgroup A' (genotype A) among Brazilian isolates of Hepatitis B virus. Arch Virol 2004, 149:1383-1395.
24. Niesters HG, De Man RA, Pas SD, Fries E, Osterhaus AD: Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J Med Microbiol 2002, 51:695-699.
25. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER, Brown NA: Brown NA. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997, 349 20-22.
26. Yeh CT, Chien RN, Chu CM, Liaw YF: Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000, 31:1318-1326.
27. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS: Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998, 28:669-673.
28. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27 1670-1677.
29. Malik AH, Lee WM: Hepatitis B therapy: the plot thickens. Hepatology 1999, 30:579-581.
30. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001, 34 785-791.
31. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, Fyfe J, Sozzi T, Jackson DC: Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002, 293 305-313.
32. Roque-Afonso MF, Ferey MP, Mackiewicz V, Fki L, Dussaix E: Monitoring the emergence of hepatits B virus polymerase gene veriants during lamivudine therapy in human immunodeficiency virus coinfeted patients: performance of CLIP sequencing and line probe assay. Antivir Ther 2003, 8:627-634.
33. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata M: The polymerase L528M mutation cooperates with nucleotide binding-site mutations increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001, 107 449-455.
34. Delaney WE 4th, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S: The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003, 77:11833-11841.
35. Neau D, Schvoerer E, Robert D, Dubois F, Dutronc H, Fleury HJ, Ragnaud JM: Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a human immunodeficiency virus-infected patient. J Infect 2000, 41:192-194.
36. Thabut D, Thibault V, Benhamou Y, Bernard B, Aubron-Olivier C, Poynard T, Di Martino V: Successful control of subfulminant hepatitis related to lamivudine-resistant hepatitis B virus in an HIV-infected patient. AIDS 2001, 15:2463-2464.
37. Bonacini M, Kurz A, Locarnini S, Ayres A, Gibbs C: Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology 2002, 122 244-245.